A number of other research firms also recently commented on OXFD. ValuEngine downgraded Oxford Immunotec Global from a hold rating to a sell rating in a report on Wednesday, September 4th. Zacks Investment Research downgraded Oxford Immunotec Global from a buy rating to a hold rating in a report on Thursday, August 1st. Finally, TheStreet downgraded Oxford Immunotec Global from a c- rating to a d+ rating in a report on Monday, July 15th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of Hold and a consensus target price of $19.33.
OXFD opened at $16.72 on Friday. The business’s 50-day moving average is $14.01 and its two-hundred day moving average is $14.81. Oxford Immunotec Global has a 1 year low of $11.88 and a 1 year high of $18.60. The company has a debt-to-equity ratio of 0.03, a current ratio of 13.35 and a quick ratio of 12.76. The firm has a market capitalization of $461.22 million, a PE ratio of 17.72 and a beta of 0.37.
Oxford Immunotec Global (NASDAQ:OXFD) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.07. The business had revenue of $19.60 million during the quarter, compared to the consensus estimate of $19.32 million. Oxford Immunotec Global had a return on equity of 14.76% and a net margin of 208.48%. The company’s quarterly revenue was up 17.7% on a year-over-year basis. During the same quarter last year, the company earned ($0.25) earnings per share. As a group, sell-side analysts expect that Oxford Immunotec Global will post -0.17 EPS for the current year.
In other news, CEO Peter Wrighton-Smith sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $14.92, for a total value of $298,400.00. Following the completion of the sale, the chief executive officer now directly owns 404,538 shares in the company, valued at $6,035,706.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $19.90, for a total value of $59,700.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 33,000 shares of company stock valued at $496,700. 4.21% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of the stock. First Light Asset Management LLC increased its position in shares of Oxford Immunotec Global by 14.5% during the second quarter. First Light Asset Management LLC now owns 3,140,347 shares of the company’s stock worth $43,211,000 after purchasing an additional 396,868 shares in the last quarter. Grandeur Peak Global Advisors LLC increased its position in shares of Oxford Immunotec Global by 25.4% during the second quarter. Grandeur Peak Global Advisors LLC now owns 795,628 shares of the company’s stock worth $10,948,000 after purchasing an additional 160,904 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Oxford Immunotec Global by 90.3% during the second quarter. Renaissance Technologies LLC now owns 556,000 shares of the company’s stock worth $7,651,000 after purchasing an additional 263,900 shares in the last quarter. Morgan Stanley increased its position in shares of Oxford Immunotec Global by 53.2% during the second quarter. Morgan Stanley now owns 508,108 shares of the company’s stock worth $6,991,000 after purchasing an additional 176,377 shares in the last quarter. Finally, Senvest Management LLC increased its position in shares of Oxford Immunotec Global by 32.5% during the second quarter. Senvest Management LLC now owns 490,902 shares of the company’s stock worth $6,755,000 after purchasing an additional 120,329 shares in the last quarter. Hedge funds and other institutional investors own 94.09% of the company’s stock.
About Oxford Immunotec Global
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
Featured Article: Investing in Growth Stocks
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.